SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*	2. Issuer Name **and** Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
GERSUK D JOSEPH	ANGIODYNAMICS INC [ANGO]	Director / 10% Owner / X Officer (give title below) / Other (specify below)

1. Name and Address of Reporting Person*

GERSUK D JOSEPH

(Last) (First) (Middle)

603 QUEENSBURY AVE.

(Street)

QUEENSBURY NY 12804

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading Symbol
ANGIODYNAMICS INC [ANGO]

3. Date of Earliest Transaction (Month/Day/Year)
08/28/2009

4. If Amendment, Date of Original Filed (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

Director — 10% Owner

X Officer (give title below) — Other (specify below)

SVP - CFO

6. Individual or Joint/Group Filing (Check Applicable Line)

X Form filed by One Reporting Person

Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/28/2009		A		1,409	A	$0	8,865	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Non-Qualified Stock Option (right to buy)	$13.29							09/04/2010	09/04/2016	Common Stock	12,000		12,000	D	
Non-Qualified Stock Option (right to buy)	$16.33							08/15/2009	08/15/2015	Common Stock	12,500		12,500	D	
Non-Qualified Stock Option (right to buy)	$16.53							05/01/2008[1]	05/01/2014	Common Stock	40,800		40,800	D	
Non-Qualified Stock Option (right to buy)	$17.76							07/27/2008[2]	07/27/2017	Common Stock	8,750		8,750	D	
Restricted Stock Units	$0[3]							05/31/2009	05/01/2014	Common Stock	1,126		1,126	D	
Restricted Stock Units	$0							09/04/2010	09/04/2016	Common Stock	12,000		12,000	D	

Explanation of Responses:

1. Options for 25% of the shares are each exercisable on 5/1/08, 5/1/09, 5/1/10, 5/1/11, respectively.

2. Options for 25% of the total number of shares each become exercisable on 7/27/08, 7/27/09, 7/27/10, and 7/27/11.

3. Each restricted stock unit represents a contingent right to receive one share of AngioDynamics, Inc. common stock.

By: K. Wayne McDougall For: D. Joseph Gersuk   10/13/2009

** Signature of Reporting Person   Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).